Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell

Inclusion Criteria: * Stage III or IV, histologically confirmed relapsed or refractory MCL as reviewed by the SI * Is CD20 positive (by immunohistochemistry or FACS) * Is Cyclin D positive (by immunohistochemistry or FACS) * Has received prior chemotherapy (required minimum of 1 prior therapies) * Has received prior treatment with Rituxan * Has an ECOG Performance Status (PS) 0-2 * Is greater than or equal to 18 years of age * Has appropriate laboratory values (please refer to protocol for specific laboratory values) * If a history of cardiac disease is indicated, patient has an LVEF greater than or equal to 50% (MUGA) * Has a negative serum pregnancy test within 7 days prior to registration (female patients of childbearing potential) * If fertile, patient (male or female) has agreed to use an acceptable method of birth control to avoid pregnancy for the duration of the study and for a period of 2 months thereafter * Has signed a Patient Informed Consent Form * Has signed a Patient Authorization Form Exclusion Criteria: * Has other lymphomas not classified as MCL * Has had prior treatment with Gemzar and/or Novantrone * A history of known hypersensitivity to Gemzar, Novantrone, Rituxan, or any component of these drugs * Has a history of hypersensitivity to murine-cell derived therapeutics * Has a LVEF indicative of a cardiac condition (LVEF \< 50%) * Is receiving concurrent immunotherapy * Has evidence of CNS involvement * Has a serious uncontrolled intercurrent medical or psychiatric illness, including serious infection * Has a history of other malignancy within the last 5 years (except cured basal cell carcinoma of skin and carcinoma insitu of uterine cervix), which could affect the diagnosis or assessment of any of the study drugs * Is a pregnant or nursing woman * Is unable to comply with requirements of study